Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D3KY
|
||||
| Former ID |
DIB003706
|
||||
| Drug Name |
SC-106
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Discontinued in Phase 2 | [1] | ||
| Company |
Scotia Holdings plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H17N5O4
|
||||
| Canonical SMILES |
C#CC(CC(=O)O)NC(=O)CNC(=O)C1=CC(=CC=C1)N=C(N)N
|
||||
| InChI |
1S/C15H17N5O4/c1-2-10(7-13(22)23)19-12(21)8-18-14(24)9-4-3-5-11(6-9)20-15(16)17/h1,3-6,10H,7-8H2,(H,18,24)(H,19,21)(H,22,23)(H4,16,17,20)/t10-/m0/s1
|
||||
| InChIKey |
IABCGGIFHPDBCJ-JTQLQIEISA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Phospholipase A2 | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Phospholipases | ||||
| KEGG Pathway | Glycerophospholipid metabolism | ||||
| Ether lipid metabolism | |||||
| Arachidonic acid metabolism | |||||
| Linoleic acid metabolism | |||||
| alpha-Linolenic acid metabolism | |||||
| Metabolic pathways | |||||
| Ras signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Pancreatic secretion | |||||
| Fat digestion and absorption | |||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | ||||
| Reactome | Acyl chain remodelling of PC | ||||
| Acyl chain remodelling of PE | |||||
| Acyl chain remodelling of PI | |||||
| WikiPathways | Glycerophospholipid biosynthesis | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007225) | ||||
| REF 2 | US patent application no. 6,673,908, Tumor necrosis factor receptor 2. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.